Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 3Phase 1/2 1

Status

Recruiting 7Active not recruiting 5Not yet recruiting 1Completed 1

Sponsor Class

INDUSTRY 6OTHER 1

Study Type

Interventional 7

Sponsor

Cancer Type

Genitourinary 5Endocrine 1CNS 1Breast 1

Conditions

Carcinoma, Renal Cell 5von Hippel-Lindau Disease 2Pheochromocytoma 1Paraganglioma 1Carcinoma 1Breast Neoplasms 1Adenoma, Islet Cell 1

Interventions

Specimen Handling 186pembrolizumab 151Magnetic Resonance Spectroscopy 151Carboplatin 114Biopsy 104Cyclophosphamide 96Cisplatin 88Paclitaxel 79Gemcitabine 71Bevacizumab 68fludarabine 60Nivolumab 58Fluorouracil 51Radiotherapy 49Dexamethasone 47Capecitabine 47Pemetrexed 46Oxaliplatin 44Docetaxel 44Rituximab 43Leucovorin 41Doxorubicin 40venetoclax 39durvalumab 39atezolizumab 39Temozolomide 32Standard of Care 32Radiation 32Cetuximab 32130-nm albumin-bound paclitaxel 32

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Recruiting × belzutifan × 30 days × Clear all
NCT07227402 2026-06-04

LITESPARK-033

Merck Sharp & Dohme LLC

Phase 3 Recruiting
904 enrolled
Genitourinary

Carcinoma, Carcinoma, Renal Cell

NCT07405164 2026-05-29

MK-6482-043

Merck Sharp & Dohme LLC

Phase 3 Recruiting
450 enrolled
Genitourinary

Carcinoma, Renal Cell, von Hippel-Lindau Disease

NCT07489495 2026-05-29

LITESPARK-034

Merck Sharp & Dohme LLC

Phase 3 Recruiting
758 enrolled
Genitourinary

Carcinoma, Renal Cell

NCT04924075 2026-05-28

MK-6482-015

Merck Sharp & Dohme LLC

Phase 2 Recruiting
322 enrolled 1 FDA
CNSEndocrine

von Hippel-Lindau Disease, Adenoma, Islet Cell, Paraganglioma, Pheochromocytoma

NCT07049926 2026-05-26

MK-3475-03C

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
140 enrolled
Genitourinary

Carcinoma, Renal Cell

NCT07023432 2026-05-22

Belzutifan's Role in Active Surveillance Versus Treatment for Indolentmetastatic Clear Cell Renal Ccell Carcinoma (BRAVE-RCC)

M.D. Anderson Cancer Center

Phase 2 Recruiting
78 enrolled
Genitourinary

Carcinoma, Renal Cell

NCT06428396 2026-05-18

LITESPARK-029

Merck Sharp & Dohme LLC

Phase 2 Recruiting
120 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡